Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study

Lili Zhao¹, Ying Shang¹, Qiongzhen Luo², Xinqian Ma¹, Wentao Ni¹, Yukun He¹, Donghong Yang¹, Yu Xu³* and Zhancheng Gao¹*

¹Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China, ²Department of Respiratory and Critical Care Medicine, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China, ³Department of Respiratory and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing, China

Background: Community-acquired pneumonia (CAP) is a respiratory disease that frequently requires hospital admission, and is a significant cause of death worldwide. Plasma fetuin-A levels were significantly lower in patients with sepsis, but data regarding CAP are scarce. This study aimed to evaluate the usefulness of fetuin-A as a prognostic biomarker of CAP.

Methods: A multicenter cohort study on CAP was conducted between January 2017 and December 2018. Demographic and clinical data were recorded for all enrolled patients. Plasma fetuin-A levels were determined using a quantitative enzyme-linked immunosorbent assay. A Cox proportional hazards regression analysis was used to analyse the effect of variables on 30-day mortality. A logistic regression analysis was performed to assess risk factors associated with severe CAP (SCAP) and 30-day mortality. A receiver operating characteristic (ROC) curve was used to verify the association between variables and CAP prognosis. Correlations were assessed using Spearman’s test. Survival curves were constructed and compared using the log-rank test.

Results: A total of 283 patients with CAP were enrolled in this study. Fetuin-A levels were decreased in patients with CAP, especially in SCAP and non-survivors. A cox regression analysis showed that CURB-65 and fetuin-A levels were independent prognostic indicators of 30-day mortality. Via a multiple logistic regression analysis, plasma level of fetuin-A (≤ 202.86 mg/L) was determined to be the strongest independent predictor of 30-day mortality considered (odds ratio, 57.365), and also was also determined to be an independent predictor of SCAP. The area under the curve (AUC) of fetuin-A for predicting 30-day mortality was 0.871, and accuracy was high (P < 0.05). Plasma fetuin-A levels were negatively correlated with WBC, NE%, Glu, CRP, PCT, CURB-65, and pneumonia severity index scores and positively correlated with albumin level. Kaplan–Meier curves showed that lower plasma levels...
Introduction

Community-acquired pneumonia (CAP) is a common respiratory infectious disease that frequently requires hospitalization. The economic burden of CAP, and its morbidity and mortality levels are high, with ~10% of hospitalized patients requiring admission to an intensive care unit (ICU) (1, 2). Hospital mortality among patients with SCAP as high as 50% (2, 3). Early diagnosis and risk stratification for CAP reduces SCAP incidence and mortality but is particularly challenging for physicians (4, 5).

PSI and CURB-65 (confusion, urea, respiratory rate, blood pressure, age 65 and older) are the most widely used risk stratification tests (6, 7). PSI stratifies individuals with CAP into five groups based on short-term mortality risk. The determination of a patient’s PSI score requires knowledge of many indices, and score calculation takes a long time, therefore its clinical applicability is limited. CURB65 is easier to determine than PSI but predicts mortality less sensitively. Furthermore, neither score assesses the host inflammatory response, which may be helpful for evaluating CAP prognosis.

Currently, traditional and novel predictors including white blood cell (WBC) count (8), C-reactive protein (CRP) (9), procalcitonin (PCT) (10), soluble triggering receptors expressed on myeloid cells-1 (11), pro-adrenomedullin (12), and progranulin (13) levels have been shown to be valuable prognostic indicators in patients with CAP. However, their sensitivity and specificity for prognosis prediction are variable and insufficient; therefore, the identification of new predictors to improve risk stratification in patients with CAP is needed (14).

Fetuin-A, also known as a 2-Heremans-Schmid glycoprotein, was first identified in fetal serum. It is mainly synthesized by liver parenchymal cells and plays important roles in multiple biological functions, including calcification, cardiovascular diseases, insulin sensitivity, apoptosis, tumor development, diabetes, obesity, and fatty liver disease (15, 16). Plasma fetuin-A levels are reduced in patients with sepsis, suggesting that levels of fetuin-A in plasma may serve as a useful indicator of CAP prognosis (17, 18). Few prior studies have assessed plasma fetuin-A levels in patients with CAP (19, 20).

Based on previous studies, we hypothesized that plasma fetuin-A levels might be correlated with CAP risk and prognosis. Thus, the aim of this study was to clarify the precise role of fetuin-A in CAP. To determine the effectiveness of fetuin-A as an indicator of the risk of death in CAP and CAP severity, 30-day survival was the primary outcome, and SCAP was the secondary outcome assessed.

Materials and methods

Study design

Participating patients and controls

This was an observational prospective cohort study that assessed patients with CAP from January 2017 to September 2018 who were hospitalized at Peking University People’s Hospital, the Second Hospital of Jinlin University, West China Hospital, Shanghai Pulmonary Hospital, Tibet Autonomous Region People’s Hospital, and Fujian Provincial Hospital (ClinicalTrials.gov ID, NCT03093220). This study was approved by the Medical Ethics Committee of Peking University People’s Hospital (approval no.: 2016PHB202-01). Our healthy controls were volunteers from staff of Peking University People’s Hospital. Informed consent was obtained from all participating patients. The trial was funded by the Chinese Science and Technology Key Project (2017ZX10103004-006) and the National Key Research and Development Programme of China (2016YFC0903800). The funder had no role in the study design, data analysis, or outcome assessment.

Definition of CAP and SCAP

The study included subjects older than 18 years meeting the following diagnostic criteria specified in diagnosis of community-acquired pneumonia in adults (21): (1) onset of symptoms in the community; (2) a chest radiograph showing either a new patchy infiltrate, leaf or segment consolidation, ground glass opacity, or interstitial change; (3) either (a) the presence of cough, sputum production, and dyspnea; (b) core body temperature > 38.0°C; (c) auscultatory findings of abnormal breath sounds and rates; or (d) peripheral white blood cell count >10 × 10^9/L or < 4 × 10^9/L. The following exclusion
criteria were applied: (1) age < 18 years; (2) patients with active tuberculosis; (3) pregnancy; (4) malignant lung tumor; (5) pulmonary interstitial disease; (6) pulmonary embolism; (7) pulmonary vasculitis; and (8) human immunodeficiency virus infection. Severe CAP (SCAP) was diagnosed based on the presence of at least one major criterion or at least three minor criteria. The criteria are almost identical to those for diagnosis CAP & SCAP by the American Thoracic Society (22).

Study aims
In the study, 30-day survival was the primary outcome assessed, and SCAP was the secondary outcome considered.

Data collection and follow-up
Clinical characteristics including sex, age, and the presence of comorbidities (chronic cardiac disease, chronic renal disease, chronic liver disease, high blood pressure, diabetes mellitus, and malignant diseases), and laboratory findings including WBC count, percentage of neutrophils (NE%), blood biochemistry, blood gas analysis, CRP, and PCT were recorded within 24 h of admission. Simultaneously, PSI and CURB-65 scores were calculated for all patients. Drug treatment after admission, complications, ventilation, survival time, mortality and SCAP were also recorded. The loop-mediated isothermal amplification method was used to detect bacteria, viruses, and fungi from respiratory-derived specimens in patient.

Measurement of fetuin-A levels
Blood samples were collected in anticoagulant tubes within 24 h of admission, and centrifuged immediately. Supernatants of plasma samples were stored at -80°C for further analysis. Plasma fetuin-A levels were measured using quantitative ELISA kits (DFTA00, R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s instructions. Briefly, the absorbance of standard and plasma samples at 450 nm was measured using a Multiskan FC system (Thermo, Waltham, MA, USA) with the correction wavelength set at 570 nm. A standard curve was created using a standard sample using a four-parameter logistic curve fit, and plasma fetuin-A levels were calculated based on the curve created.

Statistical analysis
Continuous variables are presented as mean ± standard deviation or median (interquartile range), and were assessed using an unpaired t-test or Mann–Whitney U-test, as appropriate. Categorical variables are presented as frequencies and percentages, and were analyzed using either chi-square, Fisher’s exact, or correction for continuity chi-square tests, as appropriate. Cox proportional hazards regression analyses were used to analyse effects of variables on 30-day survival.

Fetuin-A levels were categorized into four groups according to percentiles, as follows: group 1, ≥ 365.92 mg/L (50th percentile); group 2, 271.54–365.92 mg/L (25th percentile); group 3, 202.86–271.54 mg/L (10th percentile); group 4, < 202.86 mg/L (5th percentile). Using group 1 as a reference, logistic regression models were used to calculate odds ratios (ORs) for groups 2, 3, and 4. Further, ORs for groups IV and V of PSI were calculated using Groups I-III (PSI) as reference, and OR for scores (2–5) of CURB-65 were calculated using 0-1 (CURB-65) as reference. Logistic regression analyses were used to assess effects of an array of variables on SCAP. Receiver operating characteristic (ROC) curves were used to evaluate the accuracy by which different variables predicted 30-day mortality in patients with CAP. Correlations between non-normally distributed variables were assessed using the Spearman’s rho test. Kaplan–Meier methods were used to build 30-day survival curves, and values were compared using the log-rank test.

All primary and secondary outcome analyses were performed using SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA), GraphPad Prism version 8 software (GraphPad Software, La Jolla, CA, USA), and MedCalc statistical software v.15.2.2 (MedCalc). A two-sided value of \( P < 0.05 \) was considered statistically significant (\( ^* P < 0.05, ^{**} P < 0.01, ^{***} P < 0.001, ^{****} P < 0.0001 \)).

The sample size and power calculation for the Cox proportional hazards regression of the survival analysis was as follows:

\[
N = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2}{\sigma^2 B^2 P}
\]

In this study, we set the two-sided significance level to \( \alpha = 0.05 \). According to the above formula, with a sample size of 283, the standard deviation (\( Z1-\alpha/2 \)) was 1.96, 30-day mortality \( P = 0.0671 \), the R-squared value of fetuin-A with CURB-65 was 0.094, the standard deviation of fetuin-A \( \sigma \) was 137.55, the log hazard ratio of fetuin-A (B) was −0.012, and the calculated power was 0.999.

Results
Demographic characteristics and laboratory findings of enrolled patients with CAP and healthy controls are presented in Table 1. There were 85 missing values in overall 9,339 statistical values, with a missing rate of 0.91%. Using the MCAR test, the missing values were shown to be completely missing at random (\( P = 0.381 \)). Important indicators (including survival time, 30-day survival outcomes, SCAP plasma fetuin-A levels, PSI and CURB65 scores) were free of missing
TABLE 1  Clinical characteristics and laboratory findings of survivors and non-survivors.

|                         | Survivors (I) | Non-survivors (II) | Control | P-value (I vs. II) |
|-------------------------|---------------|---------------------|---------|-------------------|
| **Male sex (%)**        | 161 (60.98%)  | 13 (68.42%)         | 17 (47.22%) | 0.520             |
| **Age (years)**         | 66 (54–76)    | 70 (65–78)          | 47 (42–52) | 0.081             |
| **Comorbidities, n (%)**|               |                     |         |                   |
| Heart dysfunction       | 23 (8.71%)    | 0 (0.00%)           | 2 (5.56%) | 0.381             |
| Chronic renal disease   | 15 (5.68%)    | 0 (0.00%)           | 1 (2.78%) | 0.609             |
| Liver disease           | 12 (4.55%)    | 0 (0.00%)           | 1 (2.78%) | 1.000             |
| Diabetes mellitus       | 59 (22.35%)   | 2 (10.53%)          | 2 (5.56%) | 0.357             |
| High pressure           | 91 (34.47%)   | 5 (26.32%)          | 5 (13.89%) | 0.468             |
| **Laboratory findings** |               |                     |         |                   |
| WBC count (×10^3/mm^3)  | 6.80 (5.00–10.60) | 10.70 (4.40–17.20) | 5.42 (4.76–7.31) | 0.199             |
| NE%                     | 73.90 (61.20–82.80) | 87.10 (83.60–93.00) | 53.05 (50.40–58.03) | <0.0001           |
| Hemoglobin level (g/dL) | 128.00 (125.00–148.00) | 132.00 (112.00–148.00) | 148.00 (130.50–154.75) | 0.323             |
| Platelet count (×10^3/mm^3) | 203.00 (147.00–273.00) | 186.00 (180.00–311.00) | 239.00 (224.00–273.25) | 0.918             |
| Glucose (mmol/L)        | 5.60 (4.85–7.03) | 7.00 (4.85–8.64)    | 5.36 (4.85–5.90)    | 0.107             |
| Albumin (g/L)           | 36.00 (32.00–39.00) | 27.80 (23.40–33.00) | 45.40 (43.23–46.78) | 0.0001            |
| Blood urea nitrogen (mmol/L) | 4.90 (3.78–6.40) | 5.90 (5.00–10.70)   | NA      | 0.007             |
| CRP (mg/L)              | 39.70 (8.50–114.75) | 136.00 (88.62–185.00) | NA      | 0.0004            |
| PCT (µg/L)              | 0.11 (0.05–0.65) | 1.30 (0.18–4.16)    | NA      | 0.001             |
| **Complications, n (%)**|               |                     |         |                   |
| Sepsis                  | 22 (8.33%)    | 12 (63.16%)         | NA      | <0.0001           |
| Pleural effusion        | 91 (34.47%)   | 11 (57.89%)         | NA      | 0.040             |
| ARDS                    | 5 (1.89%)     | 11 (57.89%)         | NA      | <0.0001           |
| Confusion               | 8 (3.03%)     | 4 (21.05%)          | NA      | 0.002             |
| Non-invasive ventilation, n (%) | 146 (55.30%) | 2 (10.53%)          | NA      | 0.0002            |
| Invasive ventilation, n (%) | 15 (5.68%)  | 17 (89.47%)         | NA      | <0.0001           |
| ICU admission, n (%)    | 35 (13.25%)   | 16 (84.21%)         | NA      | <0.0001           |
| **Pathogens, n (%)**    |               |                     |         |                   |
| Bacteria                | 60 (22.73%)   | 3 (15.79%)          | NA      | 0.677             |
| Virus                   | 75 (28.41%)   | 4 (21.05%)          | NA      | 0.490             |
| Fungus                  | 19 (7.20%)    | 1 (5.26%)           | NA      | 1.000             |
| Mixed                   | 82 (31.06%)   | 8 (42.11%)          | NA      | 0.318             |
| **Drug treatment, n (%)**|             |                     |         |                   |
| Antibiotics             | 259 (98.11%)  | 19 (100.00%)        | NA      | 1.000             |
| Antiviral drugs         | 31 (11.74%)   | 13 (68.42%)         | NA      | <0.0001           |
| Corticosteroids         | 38 (14.39%)   | 9 (47.37%)          | NA      | 0.001             |
| PSI                     | 78 (59–96)    | 96 (85–118)         | NA      | 0.0004            |
| CURB-65                 | 1 (0–1)       | 2 (1–2)             | NA      | <0.0001           |
| Severe CAP, n (%)       | 39 (14.77%)   | 18 (94.74%)         | NA      | <0.0001           |

Data are presented as means ± standard deviation from the mean, or median (interquartile range) or n (%). WBC, White blood cell; NE%, percentage of neutrophils; CRP, C-reactive protein; PCT, procalcitonin; ARDS, Acute Respiratory Distress Syndrome; PSI, Pneumonia Severity Index; CURB-65, confusion, urea > 7 mmol/L, respiratory rate ≥ 30 breaths/min, low blood pressure, and age ≥ 65 years; NA, not applicable.

Values in our study. Therefore, the missing values were directly deleted in follow-up analysis. The 283 patients enrolled from January 2017 to September 2018 were divided into survivor and non-survivor groups. Thirty-day mortality in patients with CAP was 6.71% (n = 19). There were no significant between-group differences observed in terms of sex, age, comorbidities, WBC count, hemoglobin level, platelet count, glucose level, or antibiotic use. Laboratory analyses revealed that patients in the non-surviving group had higher NE%, blood urea nitrogen, CRP, and PCT, and lower levels...
FIGURE 1
Levels of plasma Fetuin-A in groups of patients considered. (A) Levels of Fetuin-A in patients with community-acquired pneumonia (CAP) and healthy individuals. (B) Comparison of Fetuin-A levels in CAP patients with different disease etiologies. (C) Levels of Fetuin-A in patients with and without severe community-acquired pneumonia (SCAP). (D) Levels of Fetuin-A among CAP survivors and non-survivors. (E) Levels of Fetuin-A in patients classified as high (V), middle (IV), and low risk based on PSI ($P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$).

A comparison of plasma fetuin-A levels

As shown in Figure 1A, plasma fetuin-A levels in patients with CAP were 371.8 ± 137.6 mg/L, a value significantly lower than that of healthy individuals (585.1 ± 107.2 mg/L, $P < 0.0001$). Pathogens detected in patients with CAP were classified as follows: bacterial, viral, fungal, mixed, or of unknown type. Levels of fetuin-A in patients with different causative pathogens of CAP differed using ANOVA analysis method ($P < 0.05$). Fetuin-A levels were significantly higher in healthy individuals than patients with CAP caused by each pathogen considered ($P < 0.0001$ for each comparison; Figure 1B).

Various metrics were applied to assess CAP severity. Patients with SCAP had lower levels of Fetuin-A (254.1 ± 94.35 mg/L) than both patients with CAP who did not have SCAP (401.4 ± 130.8 mg/L) and those of the control group (585.1 ± 107.2 mg/L; $P < 0.001$ for both). Levels of fetuin-A in control, non-SCAP, and SCAP groups tended to decrease ($P < 0.001$; Figure 1C). Similarly, the mean fetuin-A level of the non-survivor group was 219.9 ± 67.56 mg/L, notably lower than that of the survivor group (382.7 ± 134.9 mg/L; $P < 0.0001$; Figure 1D). Plasma fetuin-A levels were significantly lower in patients classified via PSI as high-risk (V) than in those classified as middle (IV) ($P < 0.01$) and low risk (I–III) ($P < 0.0001$; Figure 1E). Similarly, fetuin-A levels in middle-risk PSI (IV) patients were significantly lower than those who were determined to be low risk (I–III) ($P < 0.001$).
The concentration of fetuin-A decreased, mortality increased, and the OR for group 3 was 19.189 (P = 0.008) and for group 4 was 57.365 (5.768–570.488). As the concentration of fetuin-A decreased, mortality increased, and the OR for group 3 was 19.189 (P = 0.008) and for group 4 was 57.365 (5.768–570.488), respectively, which showed that fetuin-A concentrations were significantly elevated versus group 1 (p = 0.044 and p = 0.001, respectively).

ROC showed that plasma Fetuin-A levels had the highest accuracy for predicting the 30-day mortality in patients with CAP among all indicators assessed, with an AUC of 0.871 (95% CI: 0.826–0.907). For fetuin-A, the optimal cut-off value was determined to be 309 mg/L, which was significantly higher that of other predictors of 30-day mortality (P < 0.05; Figure 2A).

### Table 2: Cox regression analysis of risk factors associated with 30-day mortality.

| Univariate analysis | Multivariate analysis |
|---------------------|----------------------|
| **Hazard ratio (95% CI)** | **Hazard ratio (95% CI)** |
| **P-value** | **P-value** |
| Male sex | 1.375 (0.522–3.617) | 0.519 |
| Age | 1.030 (0.998–1.063) | 0.071 |
| WBC | 1.064 (1.011–1.120) | 0.017 |
| NE% | 1.096 (1.043–1.150) | 0.0002 |
| Hemoglobin level | 1.004 (0.986–1.023) | 0.663 |
| Platelet count | 1.001 (0.996–1.005) | 0.821 |
| Glucose | 1.068 (0.943–1.209) | 0.301 |
| Albumin | 0.870 (0.809–0.936) | 0.0002 |
| Blood urea nitrogen | 1.003 (0.987–1.019) | 0.718 |
| CRP | 1.006 (1.003–1.009) | <0.0001 |
| PCT | 0.997 (0.936–1.063) | 0.934 |
| PSI | 1.023 (1.010–1.036) | 0.0003 |
| CURB-65 | 2.490 (1.603–3.873) | <0.0001 |
| Fetuin-A | 0.987 (0.982–0.992) | <0.0001 |

CI, Confidence interval; WBC, White blood cell; NE%, percentage of neutrophils; CRP, C-reactive protein; PCT, procalcitonin; PSI, Pneumonia Severity Index; CURB-65, confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, low blood pressure and age ≥65 years.

### Table 3: Logistic regression analysis of risk factors associated with non-survivors.

| Univariate analysis | Multivariate analysis |
|---------------------|----------------------|
| **Odd ratio (95% CI)** | **Odd ratio (95% CI)** |
| **P-value** | **P-value** |
| PSI | Reference |
| PSI (I–III) | 3.304 (1.525–9.473) | 0.026 |
| PSI (IV) | 7.048 | 0.004 |
| PSI (V) | (1.852–26.819) |
| CURB-65 | Reference |
| (0–1) | 6.875 | <0.0001 |
| (2–5) | (2.615–18.073) | (1.476–15.064) |
| Fetuin-A | Group 1 | Reference |
| Group 1 | 6.358 | 0.112 |
| Group 2 | 4.464 | 0.289 |
| Group 3 | (271.54) | (0.432–46.124) |
| Group 4 | 10.609 | 0.044 |
| Group 4 | (271.54) | (1.071–105.052) |
| Group 4 | 4.716 | <0.0001 |
| Group 4 | (271.54) | (1.476–15.064) |

CI, Confidence interval; WBC, White blood cell; NE%, percentage of neutrophils; CRP, C-reactive protein; PCT, procalcitonin; PSI, Pneumonia Severity Index; CURB-65, confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, low blood pressure and age ≥65 years. *Adjusted for Male sex, Age, WBC, NE%, Hemoglobin level, Platelet count, Glucose, Albumin, Blood urea nitrogen, CRP, PCT.
that WBC, NE%, glucose, ALB, CRP, PCT, PSI, CURB-65, and fetuin-A were risk factors associated with SCAP via univariate logistic analyses. After adjusting for the nine predictors, three were included in the multivariate logistic analysis using the forward conditional method. ORs of NE%, CURB-65, and fetuin-A were 1.091, 7.745, and 0.990, respectively (<0.0001 for all; Table 4). Logistic regression analysis for different stratifications of fetuin-A concentrations associated with SCAP (Supplementary Table 3) revealed that as the concentration of fetuin-A decreased, the likelihood of occurrence of SCAP increased. ROC analysis showed that plasma fetuin-A level had an AUC of 0.836 for predicting 30-day mortality in CAP patients. However, no significant difference was observed when it was compared to CURB-65 and PSI (Figure 2B, Supplementary Table 4). Combining fetuin-A with CURB-65 and PSI significantly improved predictive accuracy (p < 0.0001 and p < 0.01, respectively; Figures 2C,D, Supplementary Table 4).

**Associations between predictors levels**

Relationships between plasma fetuin-A levels and clinical parameters were investigated using Spearman's correlation analyses. The resultant correlation matrix is shown in Figure 3A. Fetuin-A was found to be positively correlated with ALB, and negatively correlated with WBC (p < 0.01), NE%, Glu, CRP, PCT, CURB-65, and PSI score (p < 0.001 for all except WBC).

**Kaplan–Meier survival analysis of Fetuin-A in CAP patients**

Kaplan–Meier curves were used to assess whether plasma fetuin-A level predicted 30-day mortality in patients with CAP (Figure 3B). Patients were divided into two groups based on ROC curves thresholds, as follows: fetuin-A ≤ 309 mg/L and
TABLE 4 Logistic regression analysis of risk factors associated with SCAP.

|                      | Univariate analysis |                        | Multivariate analysis |                        |
|----------------------|---------------------|------------------------|-----------------------|------------------------|
|                      | Odd ratio (95% CI)  | P-value                | Odd ratio (95% CI)    | P-value                |
| Male sex             | 2.227 (1.153–4.303) | 0.017                  |                       |                        |
| Age                  | 1.007 (0.989–1.025) | 0.471                  |                       |                        |
| WBC                  | 1.120 (1.064–1.180) | <0.0001                |                       |                        |
| NE%                  | 1.137 (1.094–1.182) | <0.0001                |                       | 1.091 (1.045–1.139)    | <0.0001                |
| Hemoglobin level     | 0.997 (0.985–1.009) | 0.620                  |                       |                        |
| Platelet count       | 0.998 (0.995–1.001) | 0.258                  |                       |                        |
| Glucose              | 1.113 (1.014–1.220) | 0.024                  |                       |                        |
| Albuein              | 0.836 (0.789–0.885) | <0.0001                |                       |                        |
| Blood urea nitrogen  | 1.006 (0.993–1.019) | 0.399                  |                       |                        |
| CRP                  | 1.012 (1.008–1.016) | <0.0001                |                       |                        |
| PCT                  | 1.103 (1.047–1.163) | 0.0082                 |                       |                        |
| PSI                  | 1.045 (1.031–1.059) | <0.0001                |                       |                        |
| CURB-65              | 6.101                | <0.0001                | 7.745                 | <0.0001                |
| (3.658–10.176)       |                     |                        | (3.628–16.533)        |                        |
| Fetuin-A             | 0.987 (0.983–0.991) | <0.0001                | 0.990 (0.985–0.995)   | <0.0001                |

CI, Confidence interval; WBC, White blood cell; NE%, percentage of neutrophils; CRP, C-reactive protein; PCT, Procalcitonin; PSI, Pneumonia Severity Index; CURB-65, confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, low blood pressure and age ≥ 65 years.

fetuin-A > 309 mg/L. Risk of death in patients with fetuin-A levels ≤ 309 mg/L was significantly higher than that of patients with fetuin-A levels > 309 mg/L (P < 0.0001).

Comparison of plasma fetuin-A levels at discharge and admission

We only collected plasma from a small subset of patients with CAP in the 24 h before discharge (including recovery and death). Fetuin-A levels were detected in the matched plasma of these 52 patients. As shown in Figure 4A, red represents dead patients and black represents recovered patients. A total of 6 patients died, of which 5 patients had decreased plasma fetuin-A levels and fetuin-A levels were <200 mg/L before death. Plasma fetuin-A level of another dead patient increased slightly and was still at a low level of 271 mg/L. The plasma fetuin-A levels increased or were stable in most of recovered patients, while 3 recovered patients had lower fetuin-A levels of < 300 mg/L. The mean plasma fetuin-A level in recovered patients was 442 mg/L, which was higher than that of 390 mg/L in patients with CAP at admission (P = 0.03), but was still lower than that of 585 mg/L in healthy people (P < 0.0001).

ROC of plasma fetuin-A level for assessing 30-day mortality risk in 52 patients with CAP

We re-performed the analysis of plasma fetuin-A levels at admission and discharge in 52 patients to assess 30-day mortality. ROC showed that AUC of plasma fetuin-A levels at admission and discharge for predicting the 30-day mortality were 0.899 and 0.989, respectively. Fetuin-A _ change represents plasma fetuin-A level at discharge minus that of admission. ROC showed that combining fetuin-A at discharge with fetuin-A _ change (fetuin-A _ discharge and change) had the highest accuracy for predicting the 30-day mortality in patients with CAP, with an AUC of 0.993 (95% CI: 0.932–1.000), and it significantly improved predictive accuracy.
FIGURE 4
Levels of paired plasma Fetuin-A in 52 patients with CAP at admission and discharge (A). Red represents dead patients and black represents recovered patients. (B) ROC analysis of different fetuin-A level for predicting 30-day mortality. Fetuin-A _ admission represents fetuin-A levels at admission; fetuin-A _ discharge represents fetuin-A levels at discharge; fetuin-A _ change represents plasma fetuin-A level at discharge minus that of admission; fetuin-A _ Discharge and change represents combination of fetuin-A at discharge and fetuin-A _ change.

Discussion

In this prospective study of 283 patients with CAP, 30-day mortality was 6.71%, and 20.14% of patients developed SCAP. The following eight major findings were revealed: (1) plasma fetuin-A levels were reduced in patients with CAP vs. healthy individuals, especially in non-survivors and those with SCAP; (2) plasma fetuin-A level was an independent predictor of 30-day mortality; (3) the OR of the high fetuin-A level group was significantly increased vs. the low fetuin-A concentration group for predicting 30-day mortality; (4) reductions in fetuin-A levels were significantly associated with high-risk ratios of SCAP when values were adjusted for WBC, NE%, Glu, ALB, CRP, PCT, PSI, and CURB-65, and as the concentration of fetuin-A decreased, the likelihood SCAP development increased; (5) plasma fetuin-A levels most accurately predicted 30-day mortality when compared with all parameters assessed, and the accuracy increase was statistically significant; (6) combining fetuin-A with clinical severity score significantly improved SCAP predictive accuracy; (7) plasma fetuin-A levels were positively correlated with ALB and negatively correlated with WBC, NE%, Glu, CRP, PCT, CURB-65, and PSI scores; and (8) mortality rate was significantly higher in patients with fetuin-A levels < 309 mg/L than in those with fetuin levels ≥309 mg/L. Simultaneously, comparison of plasma fetuin-A levels at discharge and admission of 52 patients with CAP, plasma fetuin-A continued to decrease during the progression of CAP and <200 mg/L, patients were at extremely high risk of death. Taken together, study findings suggest that plasma fetuin-A level is an effective predictor of 30-day mortality and disease severity in patients with CAP.

An ANOVA analysis of plasma fetuin-A levels in patients infected with different causative agents of CAP revealed that pathogen type affected fetuin-A level (Figure 1B). However, no significant differences in fetuin-A levels were observed when viral and mixed infection groups were compared. Therefore, plasma fetuin-A levels were not determined to be clinically useful for evaluating pathogen type.

Fetuin-A has been widely studied in a variety of diseases including non-alcoholic fatty liver disease (23), diabetes (24), cardiovascular disease (25), sepsis (17, 18), periodontitis (26, 27), osteoarthritis (28), chronic kidney disease (29), inflammatory bowel disease (30), and encapsulating peritoneal sclerosis (31). Many of these diseases are associated with inflammation. Serum fetuin-A levels are significantly reduced in patients with sepsis and septic shock, and non-survivors have lower fetuin-A levels than survivors. Fetuin-A was negatively correlated with CRP and procalcitonin, but positively correlated with albumin. A Kaplan-Meier estimate of mortality in 102 septic patients showed that subjects whose serum fetuin-A level recovered rapidly between baseline and day 7 had improved rates of survival than those whose fetuin-A level did not rapidly recover (32). However, another study of sepsis in preterm neonates showed that fetuin-A level is not a useful prognostic indicator (18). Perhaps the differing conclusions drawn by the two studies were related to the different research subjects evaluated; adults and newborns.

Salivary and serum fetuin-A levels were significantly lower in patients with stages II–III periodontitis than healthy subjects,
and fetuin-A levels diminished as the severity of periodontal inflammation increased (27). Salivary fetuin-A levels were significantly lower in patients with chronic periodontitis than healthy individuals, and a negative correlation between fetuin-A and CRP levels was observed (26). In patients with Crohn's disease and ulcerative colitis, serum fetuin-A levels were significantly lower than that of healthy controls. Patients with inflammatory bowel disease could be distinguished from HCs with approximately 90% sensitivity and specificity via ROC analysis (30).

Few studies have examined the expression of fetuin-A in pneumonia. Only one study in children showed that serum fetuin-A levels in invasive pneumococcal disease with hemolytic uremic syndrome were significantly lower than in patients with lobar pneumonia and healthy controls; however, fetuin-A levels in lobar pneumonia did not significantly differ from those in healthy controls (19). To date, no studies have examined fetuin-A levels in adult patients with pneumonia. Our study confirmed that plasma fetuin-A levels were significantly decreased in patients with CAP. Cox proportional regression analysis showed that fetuin-A was an independent predictor of 30-day mortality in hospitalized patients with CAP after justing for other factors. Fetuin-A level can be used to successfully predict 30-day mortality rates in hospitalized CAP patients, better than those of CURB-65 and PSI. Our study revealed that combining fetuin-A level with CURB-65 and PSI significantly improved the accuracy of SCAP prediction. Combining fetuin-A level with CURB-65 and PSI significantly improved the accuracy of SCAP prediction. These data demonstrate that fetuin-A is a valuable biomarker that may be used to identify patients at high risk of SCAP development. Fetuin-A was significantly and negatively associated with CRP level, which is consistent with a previous study that assessed fetuin-A effects of inflammation (26, 32). It is an effective indicator of CAP prognosis.

Throughout the human lifespan, fetuin-A levels tend to be highest at infancy, and slightly decrease throughout childhood and adulthood, after which point they remain relatively constant (33). These differences may lead affect findings when patients of different age groups are assessed, and the specific mechanism is not fully understood.

Fetuin-A is regulated by different proinflammatory mediators. The protein functions in the acute-phase response to injury and infection, and has emerged as a multifaceted protective factor that locally counteracts calcification, modulates macrophage polarization, and attenuates inflammation and fibrosis (34–36). High mobility group box-1 (HMGB1) induces innate immune cellular expression of various cytokines, chemokines, and adhesion molecules to sustain a potentially injurious level of systemic inflammation. Fetuin-A directly inhibits HMGB1 release (34, 37). Further, fetuin-A plays a protective role against oxidative stress (38). However, the exact mechanism by which fetuin-A levels are decreased in patients with CAP remains unknown. Given the multiple roles of fetuin-A, the precise pathway by which fetuin-A functions in CAP and its potential relevance as a bioindicator deserves further exploration.

This study has two main limitations. First, healthy individuals served as the control group. The influence of other diseases on plasma fetuin-A levels could not be ruled out, and evidence for a diagnosis of CAP was slightly insufficient. Therefore, this study mainly focused on the prognostic and severity grading value of fetuin-A in CAP. Second, plasma fetuin-A levels were detected at the time of admission and only a small part of discharge, and a lack of complete paired data.

In conclusion, our results demonstrated that plasma fetuin-A levels were reduced in patients with CAP vs. healthy controls, and particularly in non-survivors and SCAP. Fetuin-A level could be used to accurately predict 30-day mortality in patients with CAP. Incorporation of fetuin-A improves the prognostic accuracy of CURB-65 and PSI. Early and ongoing detection of plasma fetuin-A levels in patients with CAP provides prognostic information, and has the potential facilitate the identification of high-risk patients.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by Medical Ethics Committee of Peking University People's Hospital (approval no.: 2016PHB202-01). The patients/participants provided their written informed consent to participate in this study.

Author contributions

LZ, YS, and ZG designed the study. LZ performed ELISA experiment. XM, WN, YH, and DY acquired clinical data. LZ, YS, QL, and XM performed data analysis. LZ and YS drafted the manuscript. YX and ZG obtained research funding. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the Chinese Science and Technology Key Project (2017ZX10103004-006), the National Key Research and Development Programme of China (2016YFC0903800), and the National and Provincial Key Clinical Specialty Capacity Building Project 2020 (Department of the Respiratory Medicine).
Acknowledgments

We would like to thank the following hospitals for their efforts and dedication in enrolling study participants: Peking University People’s Hospital, Fujian Provincial Hospital, West China Hospital, Second Hospital of Jilin University, Shanghai Pulmonary Hospital, Tibet Autonomous Region People’s Hospital. We would like to thank Editage (www.editage.cn) for English language editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. (2019) 386:448–57. doi: 10.1056/NEJMa1201334
2. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. (2015) 386:1097–108. doi: 10.1016/S0140-6736(15)60773-4
3. Pereverzova L, Uhel F, Peters Sengers H, Cremer OL, Schultz MJ, Bonten MJM, et al. Association between delay in intensive care unit admission and the host response in patients with community-acquired pneumonia. Ann Intensive Care. (2021) 11:142. doi: 10.1186/s13613-021-00930-5
4. Blasi F, Sizoli M, Piffer F. Biomarkers in lower respiratory tract infections. Palm Pharmacal Ther. (2010) 23:501–7. doi: 10.1016/j.jptpt.2010.04.007
5. Chalmers JD. Identifying severe community-acquired pneumonia: moving beyond mortality. Thorax. (2005) 70:515–6. doi: 10.1136/thoraxjnl-2005-150790
6. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. (1997) 336:243–50. doi: 10.1056/NEJM199701233360402
7. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. (2003) 58:377–82. doi: 10.1136/thorax.58.5.377
8. Meyer Sauter PM, Krausser S, Ambroggio L, Seiler M, Paioni P, Kelly C, et al. Improved diagnostics help to identify clinical features and biomarkers that predict mycoplasma pneumoniae community-acquired pneumonia in children. Clin Infect Dis. (2020) 71:1645–54. doi: 10.1093/cid/ciz1059
9. Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and total procalcitonin for 90-day mortality in hospitalized community-acquired pneumonia. Respir Res. (2018) 19:193. doi: 10.1186/s12931-018-0877-x
10. Song Y, Sun W, Dai D, Liu Y, Li Z, Tian Z, et al. Prediction value of procalcitonin combining CURB-65 for 90-day mortality in community-acquired pneumonia. Expert Rev Respir Med. (2021) 15:689–696. doi: 10.1080/17433061.2021.1665810
11. Wang Y, Zhang S, Li L, Xiao J. The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and clinical pulmonary infection score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients. Arch Gerontol Geriatr. (2019) 80:53–7. doi: 10.1016/j.archger.2018.10.005
12. Viauas D, Del Río-Pérez G, Simetti A, García-Vidal C, Acosta-Reyes J, Garavito A, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. (2016) 72:273–82. doi: 10.1016/j.jinf.2016.01.002
13. Luo Q, He X, Zheng X, Ning R, Xu Y, Yang D, et al. Elevated preprogranulin as a novel biomarker to predict poor prognosis in community-acquired pneumonia. J Infect. (2020) 80:167–73. doi: 10.1016/j.jinf.2019.12.004
14. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. Ann Transl Med. (2020) 8:609. doi: 10.21037/atm.2020.02.182
15. Jirak P, Stechemesser L, Moré E, Franzen M, Topf A, Mirna M, et al. Clinical implications of fetuin-A. Adv Clin Chem. (2019) 98:79–130. doi: 10.1016/bse.acc.2018.12.003
16. Icer MA, Yıldırım H. Effects of nutritional status on serum fetuin-A level. J Nutr Food Sci. (2020) 60:1938–46. doi: 10.1080/04080598.2019.1631751
17. Dalamaga M, Karampela I. Fetuin-A to adiponectin ratio is a promising prognostic biomarker in septic critically ill patients. J Crit Care. (2018) 44:134–5. doi: 10.1016/j.jcrc.2017.10.040
18. Degirmencioglu H, Özer Rekmez B, Derme T, Oncel MY, Canpolat FE, Tayman C. Presepsin and fetuin-A dyad for the diagnosis of proven sepsis in preterm neonates. BMC Infect Dis. (2019) 19:695. doi: 10.1186/s12879-019-4316-5
19. Janapati RP, Hsu MH, Liao WT, Chien KY, Lee HY, Chiu CH. Low serum fetuin-a as a biomarker to predict pneumococcal necrotizing pneumonia and hemolytic uremic syndrome in children. Medicine. (2016) 95:e3221. doi: 10.1097/MD.0000000000003221
20. Revéret L, Yeregui E, Olomø A, Gutiérrez-Valencia A, Buzón MJ, Martí A, et al. Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChOE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clin Transl Med. (2022) 12:e704. doi: 10.1002/ctm2.704
21. Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese thoracic society. Chinese medical association. Clin Respir J. (2018) 12:1320–1360. doi: 10.1111/crj.12674
22. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Cross J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. (2020) 208:e45-67. doi: 10.1164/rcrm.202008-1581ST
23. Lu CW, Lee YC, Chiang CH, Chang HJ, Yang WS, Huang KC. Independent dose-response associations between fetuin-A and lean nonalcoholic fatty liver disease. Nutrients. (2021) 13:2928. doi: 10.3390/nu13092928
24. Gerst F, Kemter E, Lorza-Gil E, Kaiser G, Fritz AK, Nano R, et al. The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells. Diabetologia. (2021) 64:1358–74. doi: 10.1007/s00125-021-05435-1
25. International BR. Retracted: serum fetuin-a levels in patients with cardiovascular disease: a meta-analysis. Biomed Res Int. (2020) 2020:2013691. doi: 10.1155/2020/2013691
26. Ervin Kalkan R, Onaş Dede F, Gokmenoglu C, Kara C, Salvary fetuin-A, S100A12, and high-sensitivity C-reactive protein levels in periodontal diseases. Oral Dis. (2018) 24:1554–61. doi: 10.1111/odi.12927

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.807536/full#supplementary-material
27. Nair S, Nisha KJ. Evaluation of the effect of scaling and root planing on salivary and serum fetuin-A levels in patients with stages II and III periodontitis. *J Periodontol.* (2021) 93:179–88. doi: 10.1002/JPER.21-0179

28. Favero M, Belluzzi E, Frallonardo P, Peruzzo L, Tauri L, Oliviero F, et al. Synovial fluid fetuin-A levels in patients affected by osteoarthritis with or without evidence of calcium crystals. *Rheumatology.* (2019) 58:729–30. doi: 10.1093/rheumatology/key435

29. Zhou Z, Ji Y, Ju H, Chen H, Sun M. Circulating fetuin-A and risk of all-cause mortality in patients with chronic kidney disease: a systematic review and meta-analysis. *Front Physiol.* (2019) 10:966. doi: 10.3389/fphys.2019.00966

30. Manolakis AC, Christodoulidis G, Kapsoportakis AN, Georgoulia P, Tsiaka EK, Oikonomou K, et al. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. *World J Gastroenterol.* (2017) 23:437–46. doi: 10.3748/wjg.v23.i3.437

31. Smith ER, Hewitson TD, Cai MMX, Holt SG. Fetuin-A in the peritoneal effluent of patients with encapsulating peritoneal sclerosis—more than a protein? *Kidney Int.* (2017) 92:1289–90. doi: 10.1016/j.kint.2017.07.028

32. Karampela I, Kandri F, Antonakos G, Vogiatsakis E, Christodoulatos GS, Nikolaidou A, et al. Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: a prospective study. *J Crit Care.* (2017) 41:78–85. doi: 10.1016/j.jcrc.2017.05.004

33. Robinson KN, Teran-Garcia M. From infancy to aging: biological and behavioral modifiers of fetuin-A. *Biochimie.* (2016) 124:141–9. doi: 10.1016/j.biochi.2015.12.016

34. Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection. *Curr Mol Med.* (2012) 12:625–33. doi: 10.2174/156652412800620039

35. Smith ER, Hanssen E, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. *PLoS ONE.* (2013) 8:e60904. doi: 10.1371/journal.pone.0060904

36. Rudloff S, Janet M, Rodriguera S, Dessalle K, Jahnun-Dechent W, Huynh-Du U. Fetuin-A is a HIF target that safeguards tissue integrity during hypoxic stress. *Nat Commun.* (2021) 12:549. doi: 10.1038/s41467-020-20832-7

37. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. *PloS ONE.* (2011) 6:e16945. doi: 10.1371/journal.pone.0016945

38. El-Malkey NF, Alsemeh AE, Ashour WM, Hassan NH, Edrees HM. Fetuin-A exerts a protective effect against experimentally induced intestinal ischemia/reperfusion by suppressing autophagic cell death. *Exp Biol Med.* (2021) 246:1307–17. doi: 10.1177/1533370221995520